Teva’s Copy of Tris’ QuilliChew ADHD Drug Blocked Until 2033

Tris Pharma Inc.’s QuilliChew ER won’t have to compete with Teva Pharmaceuticals USA Inc.’s generic version for at least 11 years after a New Jersey federal judge ruled the proposed copy infringes five patents for the chewable extended-release medication for attention deficit hyperactivity disorder.

Judge Kevin McNulty, in an opinion issued Tuesday in the US District Court for the District of New Jersey, found Teva’s copy “infringes all valid asserted claims,” meaning the effective date of Teva’s generic version, if approved by the US Food and Drug Administration, is Aug. 14, 2033.

The Teva Pharmaceuticals Industries ...